SNY 241220 45.00C (SNY241220C45000) Stock Options, News & Quotes

US OptionsDetailed Quotes

SNY241220C45000

Watchlist

5.10
0.000.00%

15min DelayTrading Nov 14 15:30 ET

0.00High0.00Low

Intraday

5D
Daily

News

Sanofi Updates Financials Amid Opella Stake Transfer
TipRanks11:27 ET
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
PR NewswireDec 13 08:00 ET
Sanofi Hits 23-week Low
Trading EconomicsDec 13 03:09 ET
Sanofi's Multiple Sclerosis Therapy Tolebrutinib Gets US FDA's Breakthrough Designation
MT NewswiresDec 13 01:05 ET
Gilead Sciences Names Dietmar Berger as Chief Medical Officer
MT NewswiresDec 12 17:53 ET
Sanofi's Combo Vaccines Gain FDA Fast Track Designation
Yahoo FinanceDec 12 04:34 ET

Comments

Meltyy

Sep 25 06:31

See FDA PDUFA update 👀 👇

🚨 This Week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...

Meltyy

Sep 10 04:37

📅 FDA PDUFA & AdCom Update…

📣 ITRM AdCom 9/9 meeting ongoing 🚗
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...

Trytosaveabit

Sep 9 15:10

Update

$Vir Biotechnology (VIR.US)$ $Sanofi (SNY.US)$ Reuters· 4 mins ago
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

whqqq

Sep 2 21:13

Sanofi (SNYNF) Gets a Hold from J.P. Morgan

$JPMorgan (JPM.US)$ analyst Richard Vosser has maintained a Hold rating on Sanofi with a price target of €100.00.
The stock recently closed at $113.65, with a consensus price target of $117.74, indicating a potential upside of 3.60%.
Sanofi's market cap stands at $141.1 billion, with a P/E ratio of 30.47.
$Sanofi (SNY.US)$

Meltyy

Aug 27 01:16

FDA PDUFA Update:

🚀 Buckle up for upcoming PDUFAs in September! 👇
$Travere Therapeutic (TVTX.US)$ : FILSPARI (Sparsentan)
$Avadel Pharmaceuticals (AVDL.US)$ : LUMRYZ (FT218)
$Iterum Therapeutics (ITRM.US)$ : Sulopenem - AdCom 🗓️
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Dupixent
$Vanda Pharmaceuticals (VNDA.US)$ : Tradipitant
$Zevra Therapeutics (ZVRA.US)$ : Arimoclomol
$Heron Therapeutics (HRTX.US)$ : ZYNRELEF® Vial Access Needle
$Merck & Co (MRK.US)$ : KEYTRUDA+ chemotherapy
$Bristol-Myers Squibb (BMY.US)$ : KarXT (...